Results from a retrospective study, published in the American Journal of Surgical Pathology, suggest that prognostic markers may be different in patients with SOX11-negative compared with SOX11-positive mantle cell lymphoma. 

Mantle cell lymphoma is a B-cell non-Hodgkin lymphoma with a typically aggressive clinical course. Median overall survival (OS) in this disease is relatively short (ie, 3-5 years), although more indolent disease has been observed in a subset of patients.

SOX11, which is often overexpressed at both the protein and RNA levels in mantle cell lymphoma, has been suggested as an oncogene in this disease, and as a predictor of patient outcome. However, there is conflicting evidence from studies involving small cohorts of patients with SOX11-negative disease regarding whether SOX11 status is a prognostic factor in mantle cell lymphoma.

Continue Reading

Related Articles

In this retrospective study, the clinicopathologic features of 221 patients with mantle cell lymphoma and immunohistochemical verification of SOX11 status included in a database from the MD Anderson Cancer Center, Houston, Texas, from January 1, 2004 to December 31, 2016 were assessed. Of these patients, 75 (34%) and 146 (66%) had SOX11-negative and SOX11-positive mantle cell lymphoma, respectively.

The median OS of patients with SOX11-negative mantle cell lymphoma was 36.4 months, which was not significantly different from patients with SOX11-positive mantle cell lymphoma (P =.63). Although the overall clinicopathologic features of SOX11-negative and SOX11-positive disease were similar, some differences were observed. For example, the frequencies of leukemic nonnodal disease, classic morphology, and expression of CD23 and CD200 were higher in SOX11-negative disease, and the Ki67 index was lower. While high Ki67 and blastoid/pleomorphic morphology were negative prognostic factors for patients with either SOX11-negative or SOX11-positive disease (P <.05), a high Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted shorter survival in patients with SOX11-negative (P <.0001), but not those with SOX11-positive (P =.09), disease. In addition, nodal involvement and stage III/IV disease were predictors of shorter survival in patients with SOX11-positive disease (P =.03 and P =.04, respectively) but in those with SOX11-negative disease (P =.88 and P =.74, respectively). 

“The results of this study suggest that we may need to use different prognostic factors when assessing patients with SOX11-negative versus SOX11-positive mantle cell lymphoma: Ki67, morphology, and MIPI for SOX11-negative mantle cell lymphoma; Ki67, morphology, nodal involvement, and stage for SOX11-positive mantle cell lymphoma,” the authors wrote in conclusion. 


  1. Xu J, Wang L, Li J, Saksena A, et al. SOX11-negative mantle cell lymphoma: clinicopathologic and prognostic features of 75 patients [published online February 12, 2019]. Am J Surg Pathol. doi: 10.1097/PAS.0000000000001233